JPH0556957B2 - - Google Patents
Info
- Publication number
- JPH0556957B2 JPH0556957B2 JP15677486A JP15677486A JPH0556957B2 JP H0556957 B2 JPH0556957 B2 JP H0556957B2 JP 15677486 A JP15677486 A JP 15677486A JP 15677486 A JP15677486 A JP 15677486A JP H0556957 B2 JPH0556957 B2 JP H0556957B2
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- purified
- culture
- precipitate
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 47
- 229920002674 hyaluronan Polymers 0.000 claims description 45
- 229960003160 hyaluronic acid Drugs 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 19
- 239000003957 anion exchange resin Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 description 9
- 229940010747 sodium hyaluronate Drugs 0.000 description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001721 carbon Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000642 polymer Chemical class 0.000 description 1
- -1 polypeptone Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
産業上の利用分野
本発明は、ヒアルロン酸の精製法に関する。
ヒアルロン酸は構造式
で示される多糖類の一種であり、硝子体、へその
緒、関節液、皮膚、大動脈内外膜などに含まれ、
水分の保持、湿潤剤的な役割、細菌類の侵入防止
などに役立つている。この物質は、最近、化粧
品、目、皮膚、関節などの治療剤、手術の保護剤
などとして開発されている。
従来の技術
ストレプトコツカス属のある群の細菌の莢膜成
分としてヒアルロル酸が存在することは古くから
知られている〔エイ・ピー・マクレナン(A.P.
Maclennan):ジヤーナル・オブ・ジエネラル・
マイクロバイオロジイ(J.Gen.Microbicl.)、15、
485−491、1956〕。または、糖成分3%以上の栄
養培地で通気撹拌培養を行い、ヒアルロン酸を製
造する方法が知られている(特開昭58−56692)。
従来の技術において、発酵液中に不純物として
存在する高分子化合物を除去する方法としては、
トリクロル酢酸やクロロホルム−イソアミルアル
コールで処理したり、蛋白分解酵素を使用した
り、あるいはセチルピリジウムクロライドなどで
ヒアルロン酸を選択的に沈澱させる方法などが用
いられている。
発明が解決しようとする問題点
ヒアルロン酸は、化粧品の原料としての用途が
増大し、さらに医薬品としての用途も期待されて
いる。ヒアルロン酸を医薬品として使用するに
は、蛋白質、核酸、発熱性物質などを含まない精
製品であることが必須条件である。また、その有
効性は分子量が大きく粘度が高いほどよいとも言
われている。
従来用いられるヒアルロン酸の分離精製法は、
工程が煩雑であり、使用する薬剤が高価で、また
その薬剤の毒性の問題などがあり、工業的に有利
な方法ではない。従つて、工業的に有利なヒアル
ロン酸の精製法の開発が求められている。
問題点を解決するための手段
本発明は、ヒアルロン酸や不純物として存在す
る高分子化合物が陰電荷を有する物質であること
に着目し、イオン交換樹脂を用いるヒルアロン酸
の精製法を検討した。その結果、陰イオン交換樹
脂は、一般に蛋白質、核酸、発熱性物質およびヒ
アルロン酸をよく吸着するが、ジビニルベンゼン
含量の高いマクロレテイキユラー型陰イオン交換
樹脂は、高分子のヒアルロン酸だけを吸着しない
という現象を見出し本発明を完成した。
以下に本発明を詳細に説明する。
本発明は、ヒアルロン酸を含有する液からヒア
ルロン酸を分離、精製する際に、マクロレテイキ
ユラー型陰イオン交換樹脂を用いることを特徴と
するヒアルロン酸の精製法を提供する。
本発明に用いられるマクロレテイキユラー型の
陰イオン交換樹脂とは、マクロポーラス型ともハ
イポーラス型とも称されるジビニルベンゼン含量
の高いスチレン系の陰イオン交換樹脂で、例えば
三菱化成工業社製のダイヤイオンHPA−25、
HPA−75、アンバーライト社製のIRA−900、
IRA−904などがあげられる。使用する陰イオン
交換樹脂の量は、ヒアルロン酸を2〜10g/の
範囲で含む液の量を1とした場合0.7〜1(v/
v)程度が望ましい。
本発明は、発酵法によつて得られるヒアルロン
酸を含む培養液に適用するのが好ましい。
発酵法により得られるヒアルロン酸培養液は、
ヒアルロン酸生産能を有する微生物(例えば、ス
トレプトカツコス・ズーエピデミクス
NCTC7023)を用いて、以下に示すような培養
方法で培養を行うことにより得ることができる。
培地としては、炭素源、窒素源、無機物その他
の栄養物を程よく含有するものであれば、合成培
地、天然培地のいずれも使用できる。炭素源とし
てはグルコース、シユクロース、廃糖密、澱粉加
水分解物などが使用できる。窒素源としてはペプ
トン、ポリペプトン、酵母エキス、コーンスチー
プリカー、カゼイン加水分解物、ブレイン・ハー
ト・インヒユージヨン、馬血清などの有機栄養源
の添加が望ましく、硫酸アンモニウム、硝酸アン
モニウム、塩化アンモニウム、アンモニアなどを
併用することも可能である。無機塩としては例え
ば塩化ナトリウム、リン酸ナトリウム、リン酸カ
リウム、硫酸マグネシウム、チオ硫酸ナトリウ
ム、硫酸第一鉄、硫酸マンガン、塩化カルシウ
ム、炭酸カルシウムなどが使用できる。もちろん
天然栄養源を用いたときなどに、天然物中に含有
する無機塩のみで満足させることが可能なときも
ある。また必要に応じて各種ビタミン、例えばチ
アミン、ニコチン酸、ビオチン、パントテン酸な
どが使用できる。
培養は、振盪培養、通気培養などの好気的条件
下で行う。培養温度は25〜42℃、好ましくは30〜
38℃が適当である。培養時のPHは5〜9が適当で
ある。PH調節はアンモニア水、水酸化ナトリウ
ム、水酸化カリウム、炭酸カルシウムなどによつ
て行う。
培養期間は通常2〜4日間でヒアルロン酸は主
として菌体外に蓄積する。
上記のようにして得られたヒアルロン酸培養液
からのヒアルロン酸の精製は、下記のようにして
行う。
ヒアルロン酸培養液を水でヒアルロン酸が0.5
〜2g/好ましくは1g/程度になるように
希釈し、1〜10%(v/v)程度のカーボンを添
加して15〜30℃で1時間程度撹拌して培養液と水
を混合した後、ヌツチエなどで過し液を得
る。このカーボン処理液をマクロレテイキユラー
型陰イオン交換樹脂に、空間即速度(S.V.)1〜
2(h-1)で通塔して、処理液を得る。この処理液
のPHを塩酸などで中性付近に調整して、1mol/
程度になるように塩化ナトリウムを加えた後、
アセトン、メタノール、エタノール、n−プロパ
ノール、イソ−プロパノール、などの水溶性有機
溶媒を処理液に対して1〜4倍量添加して、ヒア
ルロン酸ナトリウムの沈澱を析出させる。得られ
た沈澱を50〜100%濃度のエタノールで洗浄し、
真空乾燥して精製ヒアルロン酸を得ることができ
る。
本発明方法により得られる精製ヒアルロン酸
は、常に100cp以上の粘度を示し、極限粘度法
〔バイオキミカ・エ・バイオフイジカ・アクタ
(Biochim.Biohys.Acta)42、476、(1960)〕によ
る分子量は20万以上である。
培養液中に存在するヒアルロン酸の分子量はど
のバツチにおいても一定というわけではない。従
つて、培養液中の全ヒアルロン酸を分子量を選択
せずに精製するとその粘度は60cpから100cp程度
まて種々の粘度を示す。しかし、本発明方法によ
れば、蛋白質、核酸、発熱性物質および分子量の
小さいヒアルロン酸がマクロレテイキユラー型陰
イオン交換樹脂に吸着されるため、分子量200万
以上のヒアルロン酸が取得できる。
また、本発明は現在市販されている製品を再精
製する際にも用いることができる。現在市販され
ているヒアルロン酸は、ニワトリのトサカなどか
らの抽出物が主であるが、本発明方法で精製すれ
ば、収率はさがるものの分子量150万以上のヒア
ルロン酸の精製品を得ることができる。
市販されている製品を再精製するには、ヒアル
ロン酸ナトリウムを0.5〜2g/程度になるよ
う水に溶解したものを、マクロレテイキユラー型
陰イオン交換樹脂に、空間速度(S.V)1〜2
(h-1)で通塔して、以下はヒアルロン酸培養液の
精製と同様にして精製ヒアルトン酸ナトリウムを
得ることができる。
以下に本発明の実施例を示す。
実施例 1
ストレプトコツカス・ズーエピデミクス
NCTC 7023〔ジヤーナル・オブ・ジエネラル・
マイクロバイオロジイ(J.Gen.Microbiol.)15、
485〜491(1956)〕をブレイン・ハート・インヒユ
ージヨン寒天培地(日水製薬社製)で37℃、16時
間培養した菌体を、グルコース1%、ペプトン
1.5%、酵母エキス0.5%、コーンスチープリカー
1%、グルタミン酸ナトリウム0.3%、リン酸二
カリウム0.2%、硫酸マグネシウム0.05%、チオ
硫酸ナトリウム0.1%、炭酸カルシウム2%から
なる種培地(PH7.0)300mlに接種し、37℃、16時
間振盪培養した。この種培養液150mlをグルコー
ス2.5%、ペプトン1.5%、酵母エキス0.5%、コー
ンスチープリカー0.5%、リン酸二カリウム0.2
%、硫酸マグシウム0.005%、チオ硫酸ナトリウ
ム0.1%からなる発酵培地(PH7.2)3gを含む5
容ジヤーフアーメンターに接種し、37℃、通気
量0.3vvm、PH7.0にて26時間培養して、ヒアルロ
ン酸培養液を得た。このヒアルロン酸培養液3
をイオン交換水で20に希釈し、カーボン200g
を添加し、室温で1時間撹拌した後、ヌツチエで
過を行い、カーボン処理液20を得た。このカ
ーボン処理液から、次の3つの方法により、それ
ぞれ精製ヒアルロン酸を製造した。
(1) 対象区A
カーボン処理液20に、1.2KgのNaClを加
え、16のアセトンを添加してヒアルロン酸ナ
トリウムの沈澱を得た。この沈澱を分離しエタ
ノール洗浄、真空乾燥した結果、精製ヒアルロ
ン酸12.8gが得られた。
(2) 対象区B
カーボン処理液20に10%セチルピリジウム
クロライド(CPC)水溶液5を添加し、沈
澱物を生じさせた。この沈澱を分離、水洗後、
0.3M NaCl水溶液20に溶解し、アセトン30
を添加してヒアルロン酸ナトリウムの沈澱を
得た。この沈澱を分離し、エタノール洗浄、真
空乾燥した結果、精製ヒアルロン酸12.5gが得
られた。
(3) 試験区
カーボン処理液20を、マクロレイテイキユ
ラー型陰イオン交換樹脂ダイヤイオンHPA−
75(三菱化成工業社製)2.5に5/hで通塔
し、処理液20を得た。この処理液のPHをHC
で7.0に調整して、1.2KgのNaClを加え、16
のアセトンを添加してヒアルロン酸ナトリウム
の沈澱を得た。この沈澱を分離し、エタノール
洗浄、真空乾燥した結果、精製ヒアルロン酸
11.5gが得られた。
上記(1)〜(3)で得られた精製ヒアルロン酸の蛋白
質含量、核酸(260nmにおける吸光度)、粘度、
極限粘度を測定し、発熱性試験を行つた。その結
果を第1表に示す。
INDUSTRIAL APPLICATION FIELD The present invention relates to a method for purifying hyaluronic acid. Hyaluronic acid has the structural formula It is a type of polysaccharide represented by
It helps retain moisture, acts as a wetting agent, and prevents bacterial invasion. This substance has recently been developed as a cosmetic, a therapeutic agent for the eyes, skin, joints, etc., and a protective agent for surgery. Conventional technology It has been known for a long time that hyaluronic acid exists as a capsule component of bacteria of the genus Streptococcus [A.P. McLennan (AP
Maclennan): Journal of General
Microbiology (J.Gen.Microbicl.), 15 ,
485-491, 1956]. Alternatively, a method is known in which hyaluronic acid is produced by carrying out aerated agitation culture in a nutrient medium containing 3% or more sugar content (Japanese Patent Laid-Open No. 58-56692). In conventional technology, methods for removing high molecular compounds present as impurities in the fermentation liquid include:
Treatment with trichloroacetic acid or chloroform-isoamyl alcohol, use of proteolytic enzymes, or selective precipitation of hyaluronic acid with cetylpyridium chloride have been used. Problems to be Solved by the Invention Hyaluronic acid is increasingly being used as a raw material for cosmetics, and is also expected to be used as a pharmaceutical product. In order to use hyaluronic acid as a medicine, it is essential that it be a purified product that does not contain proteins, nucleic acids, pyrogenic substances, etc. It is also said that the larger the molecular weight and the higher the viscosity, the better the effectiveness. The conventional separation and purification method for hyaluronic acid is
This method is not industrially advantageous because the process is complicated, the chemicals used are expensive, and there are problems with the toxicity of the chemicals. Therefore, there is a need for the development of an industrially advantageous method for purifying hyaluronic acid. Means for Solving the Problems The present invention focused on the fact that hyaluronic acid and polymer compounds present as impurities are negatively charged substances, and investigated a method for purifying hyaluronic acid using an ion exchange resin. As a result, anion exchange resins generally adsorb proteins, nucleic acids, pyrogens, and hyaluronic acid well, but macroreticular anion exchange resins with a high content of divinylbenzene adsorb only polymeric hyaluronic acid. We discovered this phenomenon and completed the present invention. The present invention will be explained in detail below. The present invention provides a method for purifying hyaluronic acid characterized by using a macroreticular anion exchange resin when separating and purifying hyaluronic acid from a liquid containing hyaluronic acid. The macroreticular anion exchange resin used in the present invention is a styrene-based anion exchange resin with a high divinylbenzene content, which is also called a macroporous type or a high porous type. Diaion HPA−25,
HPA-75, IRA-900 manufactured by Amberlight,
Examples include IRA-904. The amount of anion exchange resin used is 0.7 to 1 (v/
v) degree is desirable. The present invention is preferably applied to a culture solution containing hyaluronic acid obtained by a fermentation method. Hyaluronic acid culture solution obtained by fermentation method is
Microorganisms capable of producing hyaluronic acid (e.g., Streptocatchus zooepidemics)
NCTC7023) can be obtained by culturing according to the culture method shown below. As the medium, either a synthetic medium or a natural medium can be used as long as it contains adequate amounts of carbon sources, nitrogen sources, inorganic substances, and other nutrients. As the carbon source, glucose, sucrose, waste molasses, starch hydrolyzate, etc. can be used. As a nitrogen source, it is preferable to add an organic nutrient source such as peptone, polypeptone, yeast extract, corn steep liquor, casein hydrolyzate, brain heart injection, horse serum, etc., and use in combination with ammonium sulfate, ammonium nitrate, ammonium chloride, ammonia, etc. It is also possible. Examples of inorganic salts that can be used include sodium chloride, sodium phosphate, potassium phosphate, magnesium sulfate, sodium thiosulfate, ferrous sulfate, manganese sulfate, calcium chloride, and calcium carbonate. Of course, in some cases, such as when using natural nutritional sources, it is possible to satisfy the needs only with inorganic salts contained in natural products. Further, various vitamins such as thiamine, nicotinic acid, biotin, pantothenic acid, etc. can be used as necessary. Cultivation is performed under aerobic conditions such as shaking culture and aeration culture. Culture temperature is 25~42℃, preferably 30~
38℃ is suitable. A suitable pH during culture is 5 to 9. PH adjustment is performed using ammonia water, sodium hydroxide, potassium hydroxide, calcium carbonate, etc. The culture period is usually 2 to 4 days, and hyaluronic acid is mainly accumulated outside the bacterial cells. Purification of hyaluronic acid from the hyaluronic acid culture solution obtained as described above is performed as follows. Add hyaluronic acid culture solution to water to obtain 0.5 hyaluronic acid
After diluting to about 2g/preferably 1g/adding carbon of about 1 to 10% (v/v) and stirring at 15 to 30°C for about 1 hour to mix the culture solution and water. , obtain the filtrate using Nutsuchie, etc. This carbon treatment solution is applied to a macroreticular anion exchange resin at a spatial velocity (SV) of 1 to
The treated solution is obtained by passing through the column at 2 (h -1 ). Adjust the pH of this treatment solution to around neutrality with hydrochloric acid, etc., and
After adding sodium chloride to the desired level,
A water-soluble organic solvent such as acetone, methanol, ethanol, n-propanol, iso-propanol, etc. is added in an amount of 1 to 4 times the amount of the treatment solution to precipitate sodium hyaluronate. The obtained precipitate was washed with 50-100% ethanol,
Purified hyaluronic acid can be obtained by vacuum drying. The purified hyaluronic acid obtained by the method of the present invention always shows a viscosity of 100 cp or more, and the molecular weight according to the limiting viscosity method [Biochim.Biohys.Acta 42 , 476, (1960)] is 200,000 cp or more. That's all. The molecular weight of hyaluronic acid present in the culture solution is not constant in all batches. Therefore, when all the hyaluronic acid in a culture solution is purified without selecting its molecular weight, its viscosity varies from about 60 cp to about 100 cp. However, according to the method of the present invention, proteins, nucleic acids, pyrogenic substances, and hyaluronic acid with a small molecular weight are adsorbed on the macroreticular anion exchange resin, so hyaluronic acid with a molecular weight of 2 million or more can be obtained. The present invention can also be used to repurify currently commercially available products. Currently commercially available hyaluronic acid is mainly extracted from chicken crests, etc., but if purified using the method of the present invention, a purified product of hyaluronic acid with a molecular weight of 1.5 million or more can be obtained, although the yield will be lower. can. To repurify a commercially available product, dissolve sodium hyaluronate in water to a concentration of about 0.5 to 2 g/g, and add it to a macroreticular anion exchange resin at a space velocity (SV) of 1 to 2.
(h -1 ), and purified sodium hyaltonate can be obtained in the same manner as in the purification of the hyaluronic acid culture solution. Examples of the present invention are shown below. Example 1 Streptococcus zooepidemics
NCTC 7023〔Journal of General
Microbiology (J.Gen.Microbiol.) 15 ,
485-491 (1956)] on a Brain Heart Infusion Agar medium (manufactured by Nissui Pharmaceutical Co., Ltd.) at 37°C for 16 hours.
Seed medium (PH7.0) consisting of 1.5%, yeast extract 0.5%, corn steep liquor 1%, sodium glutamate 0.3%, dipotassium phosphate 0.2%, magnesium sulfate 0.05%, sodium thiosulfate 0.1%, and calcium carbonate 2%. It was inoculated into 300ml and cultured with shaking at 37°C for 16 hours. Add 150 ml of this seed culture to glucose 2.5%, peptone 1.5%, yeast extract 0.5%, corn steep liquor 0.5%, dipotassium phosphate 0.2
5 containing 3g of fermentation medium (PH7.2) consisting of %, magnesium sulfate 0.005%, and sodium thiosulfate 0.1%.
A hyaluronic acid culture solution was obtained by inoculating the mixture into a container and culturing it at 37°C, aeration rate of 0.3 vvm, and pH 7.0 for 26 hours. This hyaluronic acid culture solution 3
diluted to 20% with ion-exchanged water and added 200g of carbon.
was added and stirred for 1 hour at room temperature, and then filtered through Nutsuie to obtain carbon treatment liquid 20. Purified hyaluronic acid was produced from this carbon treatment liquid by the following three methods. (1) Target area A 1.2 kg of NaCl was added to carbon treatment solution 20, and 16 kg of acetone was added to obtain a precipitate of sodium hyaluronate. This precipitate was separated, washed with ethanol, and dried under vacuum to obtain 12.8 g of purified hyaluronic acid. (2) Target area B 10% cetylpyridium chloride (CPC) aqueous solution 5 was added to 20 of the carbon treatment solution to form a precipitate. After separating this precipitate and washing with water,
Dissolved in 0.3M NaCl aqueous solution 20% and acetone 30%
was added to obtain a precipitate of sodium hyaluronate. This precipitate was separated, washed with ethanol, and dried under vacuum to obtain 12.5 g of purified hyaluronic acid. (3) Test area Carbon treatment solution 20 was mixed with macroretite-like anion exchange resin Diaion HPA-
75 (manufactured by Mitsubishi Chemical Industries, Ltd.) 2.5 at a rate of 5/h to obtain a treated solution 20. The pH of this treatment solution is HC
Adjust to 7.0 and add 1.2Kg of NaCl to 16
of acetone was added to obtain a precipitate of sodium hyaluronate. This precipitate was separated, washed with ethanol, and dried in vacuum, resulting in purified hyaluronic acid.
11.5g was obtained. The protein content, nucleic acid (absorbance at 260 nm), viscosity of the purified hyaluronic acid obtained in (1) to (3) above,
The intrinsic viscosity was measured and an exothermic test was conducted. The results are shown in Table 1.
【表】【table】
【表】
実施例 2
キユーピー社製ヒアルロン酸ナトリウム1gを
1の水に溶解し、三菱化成工業社製ダイヤイオ
ンHPA−75(OH)200mlに400ml/hの流速で通
液し処理液1.2を得た。処理液に含まれるヒア
ルロン酸ナトリウムの量は312mgであり、約70%
は樹脂により吸着除去された。処理液のPHを塩酸
で7.0とし70gのNaClを加えたのち1のアセト
ンを添加してヒアルロン酸ナトリウムの沈澱を得
た。この沈澱を分離し、真空乾燥して精製ヒアル
ロン酸ナトリウム305mgを得た。精製前後のサン
プルの粘度、極限粘度および分子量を実施例1と
同様の方法で測定したところ、第2表に示したと
おりであり、天然物由来のヒアルロン酸について
も、本発明方法の有効性が証明された。[Table] Example 2 1 g of sodium hyaluronate manufactured by Kewpie Corporation was dissolved in 1 part of water, and the solution was passed through 200 ml of Diaion HPA-75 (OH) manufactured by Mitsubishi Chemical Corporation at a flow rate of 400 ml/h to obtain treatment liquid 1.2. Ta. The amount of sodium hyaluronate contained in the treatment solution is 312 mg, approximately 70%
was adsorbed and removed by the resin. The pH of the treatment solution was adjusted to 7.0 with hydrochloric acid, 70 g of NaCl was added, and then 1 acetone was added to obtain a precipitate of sodium hyaluronate. This precipitate was separated and dried under vacuum to obtain 305 mg of purified sodium hyaluronate. The viscosity, intrinsic viscosity, and molecular weight of the sample before and after purification were measured using the same method as in Example 1, and the results are as shown in Table 2, demonstrating the effectiveness of the method of the present invention for hyaluronic acid derived from natural products. Proven.
【表】
発明の効果
本発明によれば、蛋白質、核酸、発熱性物質を
含まない分子量200万以上の高分子量の精製ヒア
ルロン酸を得ることができる。[Table] Effects of the Invention According to the present invention, purified hyaluronic acid having a molecular weight of 2 million or more and containing no proteins, nucleic acids, or pyrogens can be obtained.
Claims (1)
を分離、精製する際に、マクロレテイキユラー型
陰イオン交換樹脂を用いることを特徴とするヒア
ルロン酸の精製法。1. A method for purifying hyaluronic acid, which comprises using a macroreticular anion exchange resin when separating and purifying hyaluronic acid from a liquid containing hyaluronic acid.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15677486A JPS6312293A (en) | 1986-07-03 | 1986-07-03 | Purification of hyaluronic acid |
PCT/JP1987/001044 WO1989006243A1 (en) | 1986-07-03 | 1987-12-26 | Process for purifying hyaluronic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15677486A JPS6312293A (en) | 1986-07-03 | 1986-07-03 | Purification of hyaluronic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6312293A JPS6312293A (en) | 1988-01-19 |
JPH0556957B2 true JPH0556957B2 (en) | 1993-08-20 |
Family
ID=15635020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP15677486A Granted JPS6312293A (en) | 1986-07-03 | 1986-07-03 | Purification of hyaluronic acid |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6312293A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007142285A1 (en) | 2006-06-07 | 2007-12-13 | Kyowa Hakko Bio Co., Ltd. | Method for purification of hyaluronic acid salt |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60147398A (en) * | 1984-01-12 | 1985-08-03 | カシオ計算機株式会社 | Plotter functioning as reading of draft in combination |
KR100312638B1 (en) * | 1994-09-09 | 2001-12-28 | 손 경 식 | Method for manufacturing high purity hyaluronic acid |
CN100342004C (en) | 2002-08-19 | 2007-10-10 | 可隆株式会社 | Microorganism producing hyaluronic acid and purification method of hyaluronic acid |
JP2006104461A (en) * | 2004-09-10 | 2006-04-20 | Seikagaku Kogyo Co Ltd | Method for removing impurity in glycosaminoglycan fraction |
JP2008280430A (en) * | 2007-05-10 | 2008-11-20 | Mitsubishi Rayon Co Ltd | Preparation method of hyaluronic acid |
KR101639105B1 (en) | 2010-03-17 | 2016-07-12 | 덴카 주식회사 | Hyaluronic acid purification method and production method |
CN102803298B (en) | 2010-03-17 | 2015-09-23 | 电气化学工业株式会社 | Hyaluronic method of purification |
JP5560808B2 (en) * | 2010-03-23 | 2014-07-30 | 住友ベークライト株式会社 | Substrate for capturing acidic sugar chains |
JP6231993B2 (en) * | 2012-12-10 | 2017-11-15 | 三洋化成工業株式会社 | Hyaluronic acid composition |
EP3572068A1 (en) * | 2018-05-22 | 2019-11-27 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | New salt of cysteamine for the preparation of highly respirable particles |
-
1986
- 1986-07-03 JP JP15677486A patent/JPS6312293A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007142285A1 (en) | 2006-06-07 | 2007-12-13 | Kyowa Hakko Bio Co., Ltd. | Method for purification of hyaluronic acid salt |
Also Published As
Publication number | Publication date |
---|---|
JPS6312293A (en) | 1988-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3687926A (en) | Surfactin | |
DE2703615C2 (en) | ||
JPH0556957B2 (en) | ||
JPH05211882A (en) | Production of trehalose | |
JPS6232893A (en) | Production of hyaluronic acid | |
EP0346467A1 (en) | Process for purifying hyaluronic acid | |
US3033758A (en) | Preparation of levans | |
DE3247703A1 (en) | METHOD FOR PRODUCING L-THREONINE | |
JPS62289198A (en) | Novel process of producing hyaluronic acid | |
JP2721975B2 (en) | Method for producing L-lysine | |
RU2074863C1 (en) | Method of hyaluronic acid preparing | |
JPH07114695B2 (en) | Method for producing neuraminidase | |
JP3067183B2 (en) | Method for producing FR900506 substance | |
JPS6251999A (en) | Production of hyaluronic acid | |
JP2594167B2 (en) | Novel antibiotic SF2698 substance and its production method | |
JP2560257B2 (en) | Method for producing chitosan-chitin hollow fiber | |
JP2690779B2 (en) | L-ascorbic acid derivative and method for producing the same | |
KR910000454B1 (en) | Novel microorganism streptomyces sp kccb2 | |
WO1989006243A1 (en) | Process for purifying hyaluronic acid | |
KR840000378B1 (en) | Process for preparing"mildiomycin" | |
JPH0429356B2 (en) | ||
JPH09292A (en) | Glutathione-containing alga and production of glutathione | |
JPS62215397A (en) | Production of hyaluronic acid | |
JPH027631B2 (en) | ||
JP2548553B2 (en) | Method for producing glutaminase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |